Service area · Industry
tiger.PHARMA helps pharmaceutical manufacturers connect German market access strategy with an executable launch: product data, wholesale listings, availability, distribution and pharmacy ordering. Pricing, reimbursement and evidence workstreams are scoped with the relevant specialist advisers.
Discuss German market access and launch →Pharma market access · Germany · launch readiness
tiger.PHARMA helps pharmaceutical manufacturers connect German market access strategy with an executable launch: product data, wholesale listings, availability, distribution and pharmacy ordering. Pricing, reimbursement and evidence workstreams are scoped with the relevant specialist advisers.
A market access project needs distinct decisions on regulatory status, patient access, pricing and reimbursement, and commercial supply. We turn the agreed strategy into responsibilities, milestones and acceptance criteria for the German pharmacy and wholesale channels.
tiger.PHARMA Expertise
Start with the product, development stage, target market, intended channels and the decisions the project must support. Separate strategic questions from the work needed to launch and supply the product.
For products requiring an assessment of evidence, benefit or reimbursement, define the specialist workstream and its owner explicitly. tiger.PHARMA connects its outputs to the launch plan; the assignment determines which tasks are delivered directly and which require specialist partners.
IFA data, PZN, pack information, commercial terms and distributor acceptance must align. A published product record, a wholesale listing and stock that can actually be ordered are separate states.
Choose direct supply, wholesale or outsourced logistics according to the product, customers and responsibilities. Document the scope of each provider and qualify the required GDP interfaces.
Use an acceptance plan covering product data, test orders, stock, delivery and exceptions. Confirm readiness with the people responsible for commercial, quality, logistics and systems decisions.
FAQ
It covers the conditions under which a medicine can reach its intended patients and market. Product authorisation, evidence, pricing, reimbursement and an operational supply model are related but distinct workstreams.
We scope the assignment and connect the access strategy with product data, distributor listings, initial stock, supply processes and pharmacy ordering. The project identifies the relevant specialist advisers and their responsibilities.
No. Product-data publication, listing acceptance and physical availability must be checked separately. Commercial terms, stock, ordering and delivery need their own acceptance criteria.
No. Decisions depend on the product, evidence, competent institutions, partners and operational readiness. A roadmap records the dependencies and open decisions rather than promising an outcome.